First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications
Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing
NGI will deliver full end-to-end workflows using both EpiFinder cNUC and EpiFinder GenomePro
Baxfendy works in a fundamentally different way from current therapies
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The ISG assessment highlights Indegene’s deep domain expertise, proprietary technology stack, and expanding use of AI and GenAI to drive more integrated, data-led commercial execution across the life sciences value chain
Subscribe To Our Newsletter & Stay Updated
